Allarity Therapeutics (NASDAQ: ALLR) presented two scientific posters at the American Association for Cancer Research (AACR) Annual Meeting in San Diego on April 20 and 21, 2026. The posters showcased new data on stenoparib (2X‑121), a dual PARP and tankyrase inhibitor, in advanced ovarian cancer and colorectal cancer cell lines.
The first poster, titled “A Drug Response Predictor (DRP®) is associated with enhanced overall survival in the phase 2 trial in advanced, recurrent ovarian cancer patients treated twice daily with 2X‑121/stenoparib (NCT03878849),” reported that patients with high DRP® scores experienced a statistically significant improvement in overall survival compared with those with low scores. The analysis included 112 patients and demonstrated a median overall survival of 28.4 months versus 18.7 months for the low‑score cohort.
The second poster, “2X‑121/stenoparib – a novel, dual inhibitor of PARP and tankyrase in phase 2 clinical trials in advanced ovarian cancer – blocks the WNT signaling pathway and inhibits growth of human colorectal cancer cell lines at clinically relevant concentrations,” presented preclinical data showing that stenoparib effectively suppressed WNT signaling and reduced tumor cell proliferation in three colorectal cancer cell lines at concentrations below 5 µM, a range that aligns with plasma levels achieved in patients.
These findings reinforce Allarity’s strategy of pairing its proprietary DRP® platform with stenoparib to identify patients most likely to benefit. By stratifying patients based on DRP® scores, the company aims to accelerate clinical development, improve trial efficiency, and increase the likelihood of regulatory success.
Allarity’s financial position supports its ongoing development. In the fourth quarter of 2025, the company posted an earnings per share of –$0.21, beating analyst estimates of –$0.22 by $0.01. Cash and cash equivalents stood at $14.7 million as of December 31, 2025, and a $20 million debt financing completed in March 2026 is expected to extend the cash runway into mid‑2028. The company generated its first revenue of $320,000 in 2025 from licensing agreements, compared with no revenue in 2024.
CEO Thomas Jensen emphasized that the FDA Fast Track designation for stenoparib in advanced ovarian cancer underscores the drug’s clinical benefit and the potential to address unmet needs. He also highlighted the role of the DRP® platform in patient selection, which he believes will be critical for the drug’s success.
Analysts have responded positively to Allarity’s progress. Ascendiant Capital raised its price target for ALLR from $9.50 to $9.75, and the average analyst price target across the market is $9.69, reflecting growing confidence in the company’s pipeline and financial strategy.
With FDA Fast Track status, ongoing phase 2 trials, and a strengthened financial base, Allarity is positioned to advance stenoparib toward regulatory approval while maintaining a clear focus on precision oncology. The company’s dual‑inhibitor approach and patient‑selection platform could differentiate it in a competitive oncology landscape.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.